BetterLife Pharma Inc. (BETRF) intrinsic value & 10-year financials
BetterLife Pharma Inc. (BETRF) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.16
- Market cap
- $12.4M
- Revenue (FY2018)
- —
- ROIC (10-yr avg)
- -1058.0%
- Free cash flow (FY2018)
- —
BETRF 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2018 | — | -$121.2K | — | — | — | 15.9% |
| FY2017 | — | -$6.3M | — | — | — | 696.3% |
| FY2016 | — | -$8.6M | -$0.11 | — | — | 4473.6% |
| FY2015 | — | -$1.1M | -$0.10 | — | — | 310.8% |
| FY2014 | — | — | — | — | — | — |
| FY2013 | — | -$2.2M | — | — | — | 254.4% |
| FY2012 | — | -$2.5M | — | — | — | 244.4% |
| FY2011 | — | -$3.0M | — | — | — | 152.1% |
| FY2010 | — | -$120.1K | — | — | — | 8.2% |
| FY2009 | — | -$653.8K | — | — | — | -15677.7% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BetterLife Pharma Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BetterLife Pharma Inc. has historically struggled to out-earn its cost of capital, averaging just -7.9% ROIC.
BetterLife Pharma Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
BetterLife Pharma Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.